Skip to Content
Merck
CN

SML2998

Moxidectin

≥98% (HPLC)

Synonym(s):

Moxidectin, (6R,23E,25S)-5-O-Demethyl-28-deoxy-25-[(1E)-1,3-dimethyl-1-buten-1-yl]-6,28-epoxy-23-(methoxyimino)milbemycin B, 23-Methoxime-LL-F 28249α, CL 301,423, CL 301423, CL301,423, CL301423, Equest, ProHeart 6

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C37H53NO8
CAS Number:
113507-06-5
Molecular Weight:
639.82
UNSPSC Code:
12352119
NACRES:
NA.77
MDL number:
MFCD00866560

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Moxidectin, ≥98% (HPLC)

InChI

1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1

SMILES string

CO\N=C1/C[C@]2(C[C@@H]3CC(C\C=C(C)\C[C@@H](C)\C=C\C=C4/COC5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)\C(C)=C\C(C)C

InChI key

YZBLFMPOMVTDJY-LSGXYNIPSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Moxidectin is an orally active antihelminthic (antiparasitic) that targets parasite glutamate-gated chloride ion channels (GluCls). Moxidectin binding increases target GluCl permeability, resulting in influx of chloride ions and dysfunction of the excretory pore, flaccid paralysis, and death of the parasite through host response.

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

hcodes

H301,H400

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000270358
0000270358
0000272732
0000272732
0000126578

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Raj Packianathan et al.
Parasites & vectors, 13(1), 448-448 (2020-09-07)
The Australian paralysis tick, Ixodes holocyclus, causes tick paralysis in dogs and cats in the eastern coastal regions of Australia. Prevention is the best option to protect dogs against this potentially fatal disease and sarolaner provides rapid and sustained efficacy
Mahmoud Sharaf et al.
Experimental parasitology, 217, 107961-107961 (2020-08-11)
Scabies is considered one of the commonest dermatological diseases that has a global health burden. Current treatment with ivermectin (IVM) is insufficient and potential drug resistance was noticed. Moxidectin (MOX), with a better pharmacological profile may be a promising alternative.
Valentin Buchter et al.
ACS infectious diseases, 7(5), 1069-1076 (2020-09-30)
Strongyloides stercoralis is a soil-transmitted helminth affecting an estimated 30-100 million people. Since the infection may be severe and life-threatening, accessible and effective treatment is pivotal. Currently, ivermectin is the drug of choice but has limitations. Moxidectin, a veterinary anthelminthic
Csilla Becskei et al.
Parasites & vectors, 13(1), 385-385 (2020-07-31)
Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral
Molly D Savadelis et al.
Journal of veterinary internal medicine, 34(5), 1734-1745 (2020-07-22)
Administration of moxidectin topically and doxycycline PO has been utilized experimentally as an alternative treatment for heartworm disease. However, clinical effects of this protocol remain poorly characterized. To evaluate the clinical and postmortem findings associated with administration of doxycycline and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service